Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia - A comparison of three semiquantitation techniques
Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia - A comparison of three semiquantitation techniques
复制标题
DOI：
10.1309/491w-l1tn-ufqx-t61b
复制
发表时间：
2000-02-01
影响因子：
3.5
通讯作者：
Greil, R
中科院分区：
文献类型：
--
作者：
Marschitz, I;Tinhofer, I;Greil, R
许多研究表明，原癌基因bcl-2的高表达与某些肿瘤的预后不良或化疗耐药相关，但在其他肿瘤中预测良好的临床过程。然而，在这些研究中，使用了不同的Bcl-2检测免疫技术，这就提出了所用方法是否具有可比性的问题。本研究以慢性淋巴细胞白血病（CLL）细胞为研究对象，探讨免疫细胞化学、流式细胞术、免疫印迹法检测Bcl-2半定量的重复性;研究这些方法检测结果之间的一致性;研究99例CLL患者肿瘤细胞Bcl-2表达与临床参数之间的关系。我们发现，Bcl-2表达的免疫细胞化学测定是可重复的，结果与流式细胞术和免疫印迹。在患者的集体检查，Bcl-2的表达并不反映肿瘤肿块的程度，但更高的水平被发现更经常在患者进行性疾病。
A number of studies revealed that high expression of the proto-oncogene bcl-2 correlated with poor prognosis or resistance to chemotherapy in some tumors but predicted a favorable clinical course in other neoplasias. In these studies, however, different immunologic techniques for Bcl-2 detection were used, raising the question of whether the methods applied were comparable. Using chronic lymphocytic leukemia (CLL) cells, the aims of our study were as follows: (1) to determine the reproducibility of Bcl-2 semiquantitation by immunocytochemistry, flow cytometry, or immunoblotting; (2) to study the agreement between results obtained by these methods; and (3) to examine the association between Bcl-2 expression in tumor cells of 99 patients with CLL and clinical parameters. We found that determination of Bcl-2 expression by immunocytochemistry was reproducible and the results were comparable with those of flow cytometry and immunoblotting. In the patient collective examined, Bcl-2 expression did not reflect the extent of tumor mass, but higher levels were found more often in patients with progressive disease.